Should I increase dapagliflozin from 5 mg to 10 mg daily in my 66‑year‑old male patient with type 2 diabetes, A1c 7.4 %, stage 4 chronic kidney disease (eGFR ≈ 24 mL/min/1.73 m²) who is also taking glipizide 5 mg?

Should You Increase Dapagliflozin from 5 mg to 10 mg?

Do not increase the dose to 10 mg for glycemic control—dapagliflozin is likely ineffective at this eGFR (≈24 mL/min/1.73 m²) due to its mechanism of action, but you should continue 10 mg daily for cardiovascular and renal protection, not for glucose lowering. 1, 2

Critical Context: Your Patient's eGFR Disqualifies Dose Escalation for Diabetes Control

• At eGFR ≈24 mL/min/1.73 m², dapagliflozin provides negligible glucose-lowering benefit because SGLT2 inhibition requires adequate glomerular filtration to increase urinary glucose excretion. 1, 2

• The FDA label explicitly states that dapagliflozin is "not recommended for use to improve glycemic control in patients with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m²" and is "likely to be ineffective to improve glycemic control in this setting based upon its mechanism of action." 2

• Your patient's A1c of 7.4% is above target, but increasing dapagliflozin will not meaningfully lower it at this kidney function level. 1, 2

Why the Dose Should Be 10 mg—But Not for Glycemic Control

• Dapagliflozin 10 mg once daily is the evidence-based dose for cardiovascular and renal protection in patients with eGFR ≥25 mL/min/1.73 m², regardless of diabetes status or glycemic efficacy. 1, 2

• The DAPA-CKD trial—which enrolled patients with eGFR 25–75 mL/min/1.73 m² and albuminuria—demonstrated that dapagliflozin 10 mg daily reduced the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61,95% CI 0.51–0.72). 1, 3, 4

• Kidney-specific outcomes (sustained eGFR decline, end-stage renal disease, or renal death) improved by 44% (HR 0.56,95% CI 0.45–0.68), and cardiovascular death or heart failure hospitalization decreased by 29% (HR 0.71,95% CI 0.55–0.92). 1, 4

• All-cause mortality was reduced by 31% (HR 0.69,95% CI 0.53–0.88) in DAPA-CKD, providing a clear mortality benefit independent of glucose lowering. 1, 4

Practical Algorithm: What to Do Now

Step 1: Confirm the Indication for Dapagliflozin

• Your patient has stage 4 CKD (eGFR ≈24 mL/min/1.73 m²), which is just below the FDA-approved initiation threshold of eGFR ≥25 mL/min/1.73 m² for cardiovascular/renal protection. 1, 2

• However, the FDA label permits continuation of dapagliflozin 10 mg daily if eGFR falls below 25 mL/min/1.73 m² during treatment: "If the eGFR falls below 25 mL/min/1.73 m² while receiving treatment with DAPAGLIFLOZIN TABLETS, patients may continue DAPAGLIFLOZIN TABLETS 10 mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF." 2

• Because your patient is already on dapagliflozin 5 mg, you can increase to 10 mg for cardiorenal protection, even though eGFR is <25 mL/min/1.73 m². 1, 2

Step 2: Discontinue Glipizide Immediately

• Glipizide provides no cardiovascular or renal protection and increases hypoglycemia risk, especially in stage 4 CKD; it should be stopped when dapagliflozin is optimized. 1

• Combining dapagliflozin with a sulfonylurea raises hypoglycemia risk without adding cardiovascular benefit; co-administration should be avoided. 1

• Stop glipizide 5 mg completely at the time you increase dapagliflozin to 10 mg; tapering is unnecessary. 1

Step 3: Increase Dapagliflozin to 10 mg Once Daily

• The evidence-based dose for renal or cardiovascular protection is dapagliflozin 10 mg once daily, appropriate for eGFR ≥25 mL/min/1.73 m² (or continuation below 25 if already on treatment). 1, 2

• No dose titration is required; all cardiovascular and renal outcome trials used the fixed 10 mg dose. 5, 1

Step 4: Address Glycemic Control with Alternative Agents

• Because dapagliflozin will not lower A1c at this eGFR, consider adding a GLP-1 receptor agonist (e.g., liraglutide, dulaglutide, semaglutide) if eGFR improves to >30 mL/min/1.73 m²; these agents provide additional cardiovascular protection without dose adjustment. 1

• Insulin remains fully effective regardless of renal function and can be used as the primary glucose-lowering agent when aggressive glycemic control is required. 1

• DPP-4 inhibitors such as linagliptin can be used without dose adjustment at any eGFR level, though they lack the robust cardiorenal benefits of SGLT2 inhibitors and GLP-1 receptor agonists. 1

Step 5: Monitor After Dose Increase

• Re-measure eGFR 1–2 weeks after increasing dapagliflozin to 10 mg; a modest, reversible dip of 2–5 mL/min/1.73 m² is expected and should not trigger discontinuation. 1, 3

• Among patients receiving dapagliflozin in DAPA-CKD, those with an acute reduction in eGFR >10% at 2 weeks experienced a long-term eGFR decline of -1.58 mL/min per 1.73 m² per year compared with -2.44 mL/min per 1.73 m² per year among those with less pronounced reduction, indicating that the initial dip predicts better long-term renal outcomes. 3

• Closely monitor blood glucose for the first 2–4 weeks after stopping glipizide, especially if other glucose-lowering agents are still being used. 1

• Re-assess volume status at follow-up, with particular attention to elderly patients or those on diuretics. 1

Safety Precautions and Patient Education

• Inform the patient that genital mycotic infections occur in roughly 6% of dapagliflozin users versus 1% with placebo; advise daily hygiene to reduce risk. 1

• Warn about the possibility of euglycemic diabetic ketoacidosis and instruct the patient to seek immediate care for unexplained malaise, nausea, vomiting, or abdominal pain even when blood glucose is normal. 1

• Advise the patient to withhold dapagliflozin during acute illnesses with reduced oral intake, fever, vomiting, or diarrhea, and to stop the drug at least 3 days before major surgery or any procedure requiring prolonged fasting. 1, 2

• If dapagliflozin must be held temporarily, maintain a low-dose insulin regimen in insulin-requiring patients to prevent hyperglycemia. 1

Common Pitfalls to Avoid

• Do not discontinue dapagliflozin solely because eGFR is below 45 mL/min/1.73 m²; cardiorenal benefits persist despite loss of glycemic efficacy. 1

• Do not stop dapagliflozin in response to the expected early eGFR dip; the change is hemodynamic and reversible, not indicative of kidney injury. 1, 3

• Do not reduce the dapagliflozin dose below 10 mg for cardiovascular or renal indications, even at lower eGFR levels; all outcome trials used the fixed 10 mg dose. 1

• Do not combine dapagliflozin with glipizide, as the combination raises hypoglycemia risk without adding cardiovascular benefit. 1